Major molecular response achieved with dasatinib in a CML patient with F317L BCR-ABL kinase domain mutation.
Faber
Edgar
E
Mojzikova
Renata
R
Plachy
Radek
R
Rozmanova
Sarka
S
Stastny
Marek
M
Divoka
Martina
M
Jarosova
Marie
M
Indrak
Karel
K
Divoky
Vladimir
V
D019943:Amino Acid Substitution / Q000502:physiology; D000970:Antineoplastic Agents / Q000627:therapeutic use; D020732:Cytogenetic Analysis; D000069439:Dasatinib; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D006801:Humans; D007930:Leucine / Q000235:genetics; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D010649:Phenylalanine / Q000235:genetics; D017434:Protein Structure, Tertiary / Q000235:genetics; D051562:Proto-Oncogene Proteins c-bcr / Q000737:chemistry / Q000235:genetics*; D011743:Pyrimidines / Q000627:therapeutic use*; D013844:Thiazoles / Q000627:therapeutic use*; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D011743:Pyrimidines; D013844:Thiazoles; D010649:Phenylalanine; D051562:Proto-Oncogene Proteins c-bcr; D007930:Leucine; D000069439:Dasatinib